1-7 of 7
Ji-Youn Han
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial

Ross A. Soo, Urania Dafni, Ji-Youn Han, Byoung Chul Cho, Ernest Nadal, Chong Ming Yeo, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Linda Coate, Mariano Provencio, Christian Britschgi, Patrick Vagenknecht, Georgia Dimopoulou, Roswitha Kammler, Stephen P. Finn, Solange Peters, Rolf A. Stahel, for the ETOP 10-16 BOOSTER Collaborators
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (22): 5180–5191.
https://doi.org/10.1158/1078-0432.CCR-24-0932
Published: 15 November 2024
View article titled, ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Open the PDF for ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Didier Meulendijks, Wolfgang Jacob, Emile E. Voest, Morten Mau-Sorensen, Maria Martinez-Garcia, Alvaro Taus, Tania Fleitas, Andres Cervantes, Martijn P. Lolkema, Marlies H.G. Langenberg, Maja J. De Jonge, Stefan Sleijfer, Ji-Youn Han, Antonio Calles, Enriqueta Felip, Sang-We Kim, Jan H.M. Schellens, Sabine Wilson, Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Suzana Vega-Harring, Rajiv Dua, Maitram Nguyen, Lori Steiner, Celine Adessi, Francesca Michielin, Birgit Bossenmaier, Martin Weisser, Ulrik N. Lassen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5406–5415.
https://doi.org/10.1158/1078-0432.CCR-17-0812
Published: 14 September 2017
View article titled, Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Open the PDF for Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity in another window
Includes: Supplementary data
Journal Articles

Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy

Young Joo Lee, Kyong-Ah Yoon, Ji-Youn Han, Heung Tae Kim, Tak Yun, Geon Kook Lee, Hyae Young Kim, Jin Soo Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5179–5187.
https://doi.org/10.1158/1078-0432.CCR-11-0400
Published: 31 July 2011
View article titled, Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy
Open the PDF for Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Ji-Youn Han, Soo-Hyun Lee, Nam Jin Yoo, Lee Suk Hyung, Yoon Joo Moon, Tak Yun, Heung Tae Kim, Jin Soo Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (6): 1553–1560.
https://doi.org/10.1158/1078-0432.CCR-10-2525
Published: 15 March 2011
View article titled, A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers

Dae Ho Lee, Ji-Youn Han, Hong Gi Lee, Jae Jin Lee, Eun Kyoung Lee, Hyae Young Kim, Hark Kyun Kim, Eun Kyung Hong, Jin Soo Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (8): 3032–3037.
https://doi.org/10.1158/1078-0432.CCR-04-2149
Published: 18 April 2005
View article titled, Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers
Open the PDF for Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers in another window
Journal Articles

9-cis-Retinoic Acid Treatment Increases Serum Concentrations of α-Tocopherol in Former Smokers

Ji-Youn Han, Diane D. Liu, J. Jack Lee, Jonathan Kurie, Reuben Lotan, Waun K. Hong, Ho-Young Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (6): 2305–2311.
https://doi.org/10.1158/1078-0432.CCR-04-2074
Published: 23 March 2005
View article titled, 9-<em>cis</em>-Retinoic Acid Treatment Increases Serum Concentrations of α-Tocopherol in Former Smokers
Open the PDF for 9-<em>cis</em>-Retinoic Acid Treatment Increases Serum Concentrations of α-Tocopherol in Former Smokers in another window
Journal Articles

A Phase II Study of Weekly Irinotecan and Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer

Ji-Youn Han, Dae Ho Lee, Hyae Young Kim, Eun-A Kim, Jae Jin Lee, So Young Ju, Eun Hee Shin, Jin Soo Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (16): 5909–5914.
Published: 15 December 2003
View article titled, A Phase II Study of Weekly Irinotecan and Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer
Open the PDF for A Phase II Study of Weekly Irinotecan and Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer in another window